Dr. Bashar S. Alasad, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 473
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OK license 22539
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- O U Medical Center Oklahoma City, OK
- Integris Baptist Medical Center, Inc Oklahoma City, OK
- Integris Southwest Medical Center Oklahoma City, OK
- Oklahoma Heart Hospital, LLC Oklahoma City, OK
- Weatherford Regional Hospital, Inc of Weatherford Weatherford, OK
Medical groups
- Integris Ambulatory Care Corporation (685 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 473
- Services billed
- 1,681
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 612 | 223 |
| Established patient office or other outpatient visit, 20-29 minutes | 519 | 314 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 433 | 89 |
| New patient office or other outpatient visit, 45-59 minutes | 79 | 79 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 70 | 60 |
| Established patient office or other outpatient visit, 40-54 minutes | 23 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Oklahoma City, OK | 151 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Oklahoma City, OK | 147 |
| Anastrozole Other prescribers in Oklahoma City, OK | 145 |
| Prednisone Other prescribers in Oklahoma City, OK | 92 |
| Prochlorperazine Maleate Other prescribers in Oklahoma City, OK | 84 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Oklahoma City, OK | 83 |
| Jakafi (ruxolitinib phosphate) | 70 |
| Eliquis (apixaban) Other prescribers in Oklahoma City, OK | 60 |
| Alendronate Sodium Other prescribers in Oklahoma City, OK | 59 |
| Abiraterone Acetate | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 18 payments worth $445 in total to this clinician.
| Intuitive Surgical, Inc. | $73.96 |
|---|---|
| Sobi, Inc | $54.36 |
| E.r. Squibb & Sons, L.l.c. | $49.97 |
| Daiichi Sankyo Inc. | $48.69 |
| AbbVie Inc. | $33.18 |
| Array Biopharma Inc | $26.11 |
| Pfizer Inc. | $25.66 |
| Novartis Pharmaceuticals Corporation | $23.20 |
| Food and Beverage | $425 |
|---|---|
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Apr 14, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $59,779 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
Novartis Pharmaceuticals Corporation - A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First …
Novartis Pharmaceuticals Corporation - A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia
Argenx US, Inc. - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.